MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 465689 | Name: NBS-1120

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NBS-1120 is NOSH-releasing NSAID analog.

Chemical Structure

NBS-1120
NBS-1120
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 465689

Name: NBS-1120

CAS#: unknown

Chemical Formula: C20H15NO7S3

Exact Mass: 477.0011

Molecular Weight: 477.52

Elemental Analysis: C, 50.31; H, 3.17; N, 2.93; O, 23.45; S, 20.14

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
NBS-1120; NBS1120; NBS 1120;
IUPAC/Chemical Name
4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate
InChi Key
CEDNXFMUAHDZQB-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H15NO7S3/c22-18(6-3-11-26-21(24)25)28-16-5-2-1-4-15(16)20(23)27-14-9-7-13(8-10-14)17-12-19(29)31-30-17/h1-2,4-5,7-10,12H,3,6,11H2
SMILES Code
O=C(CCCO[N+]([O-])=O)OC1=C(C(OC2=CC=C(C3=CC(SS3)=S)C=C2)=O)C=CC=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 477.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chattopadhyay M, Kodela R, Santiago G, Le TTC, Nath N, Kashfi K. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS. Biochem Pharmacol. 2020 Jun;176:113857. doi: 10.1016/j.bcp.2020.113857. Epub 2020 Feb 14. PMID: 32061771; PMCID: PMC7263941. 2: Antoniou C, Xenofontos R, Chatzimichail G, Christou A, Kashfi K, Fotopoulos V. Exploring the Potential of Nitric Oxide and Hydrogen Sulfide (NOSH)-Releasing Synthetic Compounds as Novel Priming Agents against Drought Stress in Medicago sativa Plants. Biomolecules. 2020 Jan 10;10(1):120. doi: 10.3390/biom10010120. PMID: 31936819; PMCID: PMC7023404. 3: Kodela R, Chattopadhyay M, Velázquez-Martínez CA, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications. Biochem Pharmacol. 2015 Dec 15;98(4):564-72. doi: 10.1016/j.bcp.2015.09.014. Epub 2015 Sep 21. PMID: 26394025; PMCID: PMC4656078. 4: Vannini F, MacKessack-Leitch AC, Eschbach EK, Chattopadhyay M, Kodela R, Kashfi K. Synthesis and anti-cancer potential of the positional isomers of NOSH- aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid. Bioorg Med Chem Lett. 2015 Oct 15;25(20):4677-82. doi: 10.1016/j.bmcl.2015.08.023. Epub 2015 Aug 14. PMID: 26323873; PMCID: PMC4592841. 5: Vannini F, Chattopadhyay M, Kodela R, Rao PPN, Kashfi K. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling. Redox Biol. 2015 Dec;6:318-325. doi: 10.1016/j.redox.2015.08.014. Epub 2015 Aug 20. PMID: 26319435; PMCID: PMC4556775. 6: Fonseca MD, Cunha FQ, Kashfi K, Cunha TM. NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain. Pharmacol Res Perspect. 2015 Jun;3(3):e00133. doi: 10.1002/prp2.133. Epub 2015 May 8. PMID: 26236481; PMCID: PMC4492749. 7: Vannini F, Kodela R, Chattopadhyay M, Kashfi K. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism. Redox Biol. 2015 Aug;5:421. doi: 10.1016/j.redox.2015.09.033. Epub 2015 Dec 30. PMID: 28162291. 8: Kashfi K. Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents. Redox Biol. 2015 Aug;5:420. doi: 10.1016/j.redox.2015.09.030. Epub 2015 Dec 30. PMID: 28162289. 9: Drochioiu G, Tudorachi L, Murariu M. NOSH aspirin may have a protective role in Alzheimer's disease. Med Hypotheses. 2015 Mar;84(3):262-7. doi: 10.1016/j.mehy.2015.01.008. Epub 2015 Jan 14. PMID: 25636606. 10: Lee M, McGeer E, Kodela R, Kashfi K, McGeer PL. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders. Glia. 2013 Oct;61(10):1724-34. doi: 10.1002/glia.22553. Epub 2013 Aug 5. PMID: 23918470. 11: Chattopadhyay M, Kodela R, Olson KR, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem Biophys Res Commun. 2012 Mar 16;419(3):523-8. doi: 10.1016/j.bbrc.2012.02.051. Epub 2012 Feb 16. PMID: 22366248.